The Millennium Problems for Biology

You can now target intracellular proteins with engineered binders that enter cells without transfection, potentially enabling new drug modalities.

Edison Scientific has announced ten "Millennium Problems for Biology," challenging researchers to solve fundamental biological questions with significant cash prizes. These challenges span several domains, including the origins of life, cryopreservation of whole mammals, and the creation of novel enzymes. Specific problems include demonstrating the spontaneous emergence of self-replicating cells from chemical precursors in a lab, achieving high-viability cryopreservation and recovery of live mice, and developing an enzyme capable of reverse-translating peptide sequences into RNA or DNA. Other challenges focus on improving the efficiency of the Rubisco enzyme, engineering cells that use a four-base codon system, enabling limb regeneration in adult mice, producing gene therapies in bacteria, designing programmable proteases, creating cell-penetrating protein binders for intracellular targets, and achieving exponential amplification of protein sequences without a nucleic acid template. Each problem has detailed success criteria and deadlines, aiming to spur major advancements in biological sciences.

The announcement of these grand challenges signals a maturing field of synthetic biology and protein engineering, where ambitious, long-term goals are becoming tangible research objectives. The scope of these problems suggests a shift towards addressing fundamental biological processes with unprecedented precision and control, moving beyond incremental improvements to paradigm-changing breakthroughs. Success in these areas could unlock novel therapeutic strategies and a deeper understanding of life's origins and functions.

These challenges directly impact the landscape of biotechnology and pharmaceutical development by setting clear targets for innovation in areas like gene therapy production, enzyme design, and regenerative medicine. They are likely to accelerate research efforts and attract significant investment towards synthetic biology platforms and protein engineering tools. The successful resolution of even a subset of these problems could lead to entirely new classes of therapeutics and diagnostics.